| Objective:To investigate the clinical efficacy and safety of vinorelbine combined with carboplatin chemotherapy in the
treatment of advanced lung cancer.Methods:60 patients with advanced lung cancer were selected and randomly divided into the
experimental group and control group according to different treatments, 30 cases in each group. The CEA, CA50, CYFRA21-1 levels,
white blood cells count and T lymphocyte subsets CD4+, CD8+ level were compared before and after treatment.Results:No statistically
significant difference was found in the CEA, CA50, CYFRA21-1 levels, white blood cell count and T lymphocyte subsets CD4+, CD8+
levels before treatment between two groups (P>0.05). Compared with the control group, the CEA, CA50, CYFRA21-1, CD8+ levels of
experimental group were significantly lower after treatment (P<0.05), while the white blood cell count, CD4+, CD4+/CD8+ were
significantly higher after treatment (P<0.05).Conclusion:Compared with radiotherapy, vinorelbine combined with carboplatin
chemotherapy could significantly improve the clinical efficacy of advanced lung cancer and had no effect on the cellular immunity. |
